Sun Pharmaceutical Industries rose 2.21% to Rs 972.65 at 11:45 IST on BSE after foreign funds purchased bulk shares in secondary equity market on NSE yesterday, 21 April 2015.
Meanwhile, the S&P BSE Sensex was up 81.44 points or 0.29% at 27,757.48.
On BSE, so far 5.67 lakh shares were traded in the counter as against average daily volume of 4.04 lakh shares in the past one quarter.
The stock hit a high of Rs 978.65 and a low of Rs 955 so far during the day. The stock had hit a record high of Rs 1,200.70 on 7 April 2015. The stock had hit a 52-week low of Rs 572.15 on 22 May 2014.
The stock had underperformed the market over the past one month till 21 April 2015, declining 7.35% compared with the Sensex's 2.07% fall. The scrip had, however, outperformed the market in past one quarter, surging 7.4% as against Sensex's 4.2% fall.
The large-cap pharma firm has equity capital of Rs 240.61 crore. Face value per share is Re 1.
Aranda Investment Maurtius Pte bought 2.01 crore of Sun Pharmaceutical Industries (Sun Pharma) at an average price of Rs 930.16 per share. Goldman Sachs (Singapore) Pte bought 5.12 crore of Sun Pharma at an average price of Rs 930.16 per share. Government of Singapore purchased 1.26 crore shares of Sun Pharma at an average price of Rs 930.16 per share. Japan's Daiichi Sankyo Company sold a total of 21.49 crore shares of Sun Pharma at an average price of Rs 931.58 per share in these bulk deals.
Shares of Sun Pharmaceutical Industries had slumped 8.86% yesterday, 21 April 2015, after Daiichi Sankyo announced that it had completed the sale of its entire stake in the Indian company. Daiichi Sankyo sold its entire holding of 21.49 crore shares of Sun Pharma. Earlier, Daiichi had received shares of Sun Pharma in March this year following the merger of Ranbaxy Laboratories with Sun Pharma.
Meanwhile, with respect to news item titled "Daichi Sankyo to exit Company & Promoter Dilip Sanghvi may buy partial stake for 22500 crs," Sun Pharmaceutical Industries clarified during trading hours today, 22 April 2015, that promoter Dilip Shanghvi has neither purchased nor agreed to purchase any shares of the company in the said transaction.
Sun Pharmaceutical Industries' consolidated net profit dropped 6.9% to Rs 1425.07 crore on 0.2% decline in net sales to Rs 4279.54 crore in Q3 December 2014 over Q3 December 2013.
Sun Pharmaceutical Industries is an international specialty pharmaceutical company.
Powered by Capital Market - Live News
